RxDoctor Payments Data

Xiaohui Wang, PhD

Internal Medicine · Reading, MANPI 1982862967

Payments from drug & device makers

$1,479in general payments, 2019–2025

Across 60 payments — averaging $24.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$199
  • Minerva Surgical, Inc$175
  • Lilly USA, LLC$169
  • Johnson & Johnson$134
  • Gilead$112
  • Amgen$92
  • plus $599 from 12 others

What the payments were for

  • Food & beverage$1,46099%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,479 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$57,792
Medicare patients
128
Services billed
668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin32$51,055
EliquisApixaban49$45,332
JanuviaSitagliptin Phosphate13$15,571
XareltoRivaroxaban22$12,064
Breo ElliptaFluticasone/Vilanterol20$9,569
Xigduo XrDapaglifloz Propaned/Metformin11$7,220
Arnuity ElliptaFluticasone Furoate18$4,221
Atorvastatin Calcium255$4,001
Metoprolol Succinate112$1,647
Omeprazole110$1,621
Levothyroxine Sodium107$1,357
Rosuvastatin Calcium63$1,317
Losartan Potassium108$1,249
Metformin Hcl81$1,125
Amlodipine Besylate172$1,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$81$51,05532 claims
PfizerEliquis$199$45,33249 claims
MerckJanuvia$71$15,57113 claims
GSKBreo Ellipta, Arnuity Ellipta$25$13,79038 claims
Johnson & JohnsonXarelto$134$12,06422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Reading

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →